These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35351238)

  • 1. QT prolongation in the STREAM Stage 1 Trial.
    Hughes G; Bern H; Chiang CY; Goodall RL; Nunn AJ; Rusen ID; Meredith SK
    Int J Tuberc Lung Dis; 2022 Apr; 26(4):334-340. PubMed ID: 35351238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Motta I; Cusinato M; Ludman AJ; Lachenal N; Dodd M; Soe M; Abdrasuliev T; Usmanova R; Butabekov I; Nikolaevna TZ; Liverko I; Parpieva N; Moodliar R; Solodovnikova V; Kazounis E; Nyang'wa B-T; Fielding KL; Berry C
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0053624. PubMed ID: 38842323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-wave morphology abnormalities in the STREAM stage 1 trial.
    Hughes G; Young WJ; Bern H; Crook A; Lambiase PD; Goodall RL; Nunn AJ; Meredith SK
    Expert Opin Drug Saf; 2024 Apr; 23(4):469-476. PubMed ID: 38462751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ECG monitoring in STREAM Stage 1: can we identify those at increased risk of QT prolongation?
    Hughes G; Bern H; Chiang CY; Goodall RL; Nunn AJ; Rusen ID; Meredith SK
    Int J Tuberc Lung Dis; 2022 Nov; 26(11):1065-1070. PubMed ID: 36281045
    [No Abstract]   [Full Text] [Related]  

  • 5. Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: Findings of aDSM in Taiwan.
    Lin CJ; Chen JH; Chien ST; Huang YW; Lin CB; Lee JJ; Lee CH; Yu MC; Chiang CY
    J Microbiol Immunol Infect; 2024 Oct; 57(5):791-800. PubMed ID: 39160114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
    Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
    Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis.
    Abdelwahab MT; Court R; Everitt D; Diacon AH; Dawson R; Svensson EM; Maartens G; Denti P
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0268720. PubMed ID: 33875426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
    Ali AM; P Solans B; Hesseling AC; Winckler J; Schaaf HS; Draper HR; van der Laan L; Hughes J; Fourie B; Nielsen J; Wiesner L; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0079423. PubMed ID: 38112526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
    Liu F; Gao J; Gao M; Liu Y; Shu W; Xie L; Sun Y; Zhang L; Li L; Pang Y
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0203321. PubMed ID: 36047781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
    Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
    Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis.
    Li H; Salinger DH; Everitt D; Li M; Del Parigi A; Mendel C; Nedelman JR
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
    Brust JCM; Gandhi NR; Wasserman S; Maartens G; Omar SV; Ismail NA; Campbell A; Joseph L; Hahn A; Allana S; Hernandez-Romieu AC; Zhang C; Mlisana K; Viljoen CA; Zalta B; Ebrahim I; Franczek M; Master I; Ramangoaela L; Te Riele J; Meintjes G
    Clin Infect Dis; 2021 Dec; 73(11):2083-2092. PubMed ID: 33882121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline Effect on QT Interval of Drugs-Resistant Tuberculosis Patients: Real World Data.
    Darmayani IGAAPS; Ascobat P; Instiaty I; Sugiri YJR; Sawitri N
    Acta Med Indones; 2022 Jul; 54(3):389-396. PubMed ID: 36156479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort Study.
    Isralls S; Baisley K; Ngam E; Grant AD; Millard J
    Open Forum Infect Dis; 2021 Aug; 8(8):ofab413. PubMed ID: 34466629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects.
    Kelleher D; Tombs L; Preece A; Brealey N; Mehta R
    Pulm Pharmacol Ther; 2014 Oct; 29(1):49-57. PubMed ID: 25020273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
    Yoon HY; Jo KW; Nam GB; Shim TS
    Int J Tuberc Lung Dis; 2017 Sep; 21(9):996-1001. PubMed ID: 28826448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
    Kuchimanchi M; Dabrowski C; Lu S; Melhem M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.
    Dixon R; Job S; Oliver R; Tompson D; Wright JG; Maltby K; Lorch U; Taubel J
    Br J Clin Pharmacol; 2008 Sep; 66(3):396-404. PubMed ID: 18662287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy and Safety of Moxifloxacin and Levofloxacin in a Short Standardised Rifampicin Resistant TB Regimen: A STREAM 2 Secondary Analysis.
    Fabiane SM; Chiang CY; Meredith SK; Gurumurthy M; Bayissa A; Nunn AJ; Goodall RL;
    Trop Med Infect Dis; 2024 Sep; 9(9):. PubMed ID: 39330900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.